Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML

Lancet Haematol. 2018 Jan;5(1):e6-e7. doi: 10.1016/S2352-3026(17)30229-6. Epub 2017 Dec 11.

Authors

Aditi Shastri¹, Amit K Verma²

Affiliations

¹ Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA. Electronic address: [email protected].
² Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA.

PMID: 29241763
DOI: 10.1016/S2352-3026(17)30229-6

No abstract available

MeSH terms

Benzoates / pharmacology*
Clinical Trials as Topic
Humans
Hydrazines / pharmacology*
Leukemia, Myeloid, Acute / complications*
Myelodysplastic Syndromes / complications*
Pyrazoles / pharmacology*
Risk
Thrombocytopenia / complications*
Thrombocytopenia / prevention & control*

Substances

Benzoates
Hydrazines
Pyrazoles
eltrombopag